Disitamab vedotin

Disitamab vedotin (RC48) is a HER2-targeted antibody-drug conjugate developed by RemeGen in China and licensed to Seagen (now a Pfizer subsidiary) for ex-China markets in a 2021 deal worth $200M upfront plus up to $2.4B in milestones [7]. It is already approved in China under the brand Aidixi for HER2-positive gastric and HER2-expressing urothelial cancers, but has no US or EU approval. Pfizer's Western Phase 3 program is NCT05911295: disitamab vedotin plus pembrolizumab (Merck's Keytruda) versus platinum chemotherapy in previously untreated HER2-expressing metastatic urothelial cancer, powered on progression-free survival (PFS, the time from randomization until the tumor grows or the patient dies) by blinded independent central review in 412 patients [3]. What matters commercially: this trial is trying to carve into a first-line bladder cancer setting that Padcev (enfortumab vedotin, also owned by Pfizer via Seagen) plus pembrolizumab already dominates after KEYNOTE-A39/EV-302 displaced platinum chemo as standard of care in late 2023 [6]. A statistical win is plausible, a category-shifting win is not.

Not a novel compound. Disitamab vedotin was approved in China by RemeGen in 2021 for HER2-overexpressing gastric cancer and later in HER2-expressing urothelial cancer, with in-China sales in the low hundreds of millions of dollars annually. Outside China the asset belongs to Pfizer via the Seagen acquisition completed December 2023 [5]. RemeGen retains Asia (ex-Japan and Singapore) rights and continues to receive milestones and tiered royalties on ex-China sales under the 2021 licensing agreement [7], so a Western success flows partially back to RemeGen and is not fully captured by Pfizer. No US or EU marketing authorization exists for any indication. Public disclosures do not indicate FDA breakthrough therapy, fast track, or orphan drug designations for the urothelial program specifically. Per ClinicalTrials.gov, the Phase 3 NCT05911295 is active but not recruiting, meaning the 412-patient target enrollment is complete or effectively closed [3]. Primary readout is PFS by blinded central review. Pfizer has not publicly guided to a topline data window, but with accrual closed a 2026 or 2027 readout is the plausible range depending on PFS event maturity. A supporting Phase 2 (NCT04879329) is still enrolling cohorts to characterize the disitamab vedotin plus pembrolizumab combination [4], and two follow-on Phase 2 programs (NCT06003231 and NCT06157892) are testing the ADC as a single agent in pretreated HER2-expressing tumors and in combination with other agents in solid tumors. Even in a positive-Phase-3 scenario, first US approval is unlikely before 2027.

HER2 is a growth-signal receptor that sits on the cell surface and tells the cell to divide. Some cancers make far more HER2 than normal cells and become dependent on that signal. HER2 expression is measured on a 0 to 3+ scale using immunohistochemistry (IHC), a protein stain applied to biopsy tissue. IHC 3+ means the cell surface is densely coated with HER2 receptors, 2+ is moderate staining, 1+ is faint but detectable, and 0 is no visible staining. Disitamab vedotin is an antibody-drug conjugate: a HER2-binding antibody is chemically linked to a chemotherapy payload called MMAE (monomethyl auristatin E, a microtubule poison that stops cells from dividing). The antibody finds HER2-expressing tumor cells, the complex is pulled inside, the linker is cleaved, and MMAE is released to kill the cell. Because the linker is cleavable, released MMAE can also leak into neighboring HER2-low cells (the bystander effect), which is why the drug is being tested in patients scoring IHC 1+, not just IHC 3+ [1]. Payload matters when comparing ADCs. Disitamab vedotin uses MMAE (a tubulin inhibitor with a moderate bystander effect and a class-typical toxicity profile of peripheral neuropathy, neutropenia, and alopecia). Trastuzumab deruxtecan (T-DXd) uses deruxtecan, a topoisomerase I inhibitor with a higher drug-to-antibody ratio and a stronger bystander effect, which is a leading explanation for why T-DXd works robustly in HER2-low breast cancer and shows activity across many HER2-low tumors, including a pan-tumor bladder cohort in DESTINY-PanTumor02 [2]. It is also why T-DXd carries a distinctive interstitial lung disease risk that MMAE ADCs do not. HER2 as an oncology target is thoroughly validated. Trastuzumab, pertuzumab, T-DM1, T-DXd, lapatinib, and neratinib are all approved in breast or gastric cancers, and T-DXd works even in HER2-low disease. In bladder cancer the story is different. Roughly 15 to 25% of metastatic urothelial tumors are HER2-high (IHC 2+ or 3+), and earlier trastuzumab studies disappointed because HER2 signaling was not a hard dependency in these tumors [1]. Once the IHC 1+ threshold used in NCT05911295 is applied, published estimates put the HER2-expressing fraction of metastatic urothelial cancer at roughly 40 to 60%, so the trial's eligibility criterion intentionally broadens the addressable population well beyond HER2-high disease. The ADC approach turns the antibody into a delivery vehicle for chemo, which is the whole reason a HER2-low or HER2-modest tumor can still respond.

NCT05911295 randomizes 412 previously untreated patients with locally advanced or metastatic HER2-expressing urothelial carcinoma to disitamab vedotin plus pembrolizumab versus investigator-choice platinum-based chemotherapy (cisplatin or carboplatin with gemcitabine) [3]. HER2 expression is defined broadly as IHC 1+, 2+, or 3+, capturing most patients with any detectable staining rather than only HER2-high tumors. Primary endpoint is PFS by blinded independent central review, with overall survival (OS, the time from randomization until death from any cause) as a key secondary. Sponsor of record is Seagen, a wholly owned Pfizer subsidiary. Status is active, not recruiting, so enrollment is closed. The design has one glaring problem that had nothing to do with the sponsor's execution and everything to do with timing: the platinum chemo comparator was standard of care when the trial was designed, but EV-302/KEYNOTE-A39 replaced it in 2024 with enfortumab vedotin plus pembrolizumab (median OS 31.5 months vs 16.1 months for platinum chemo, HR 0.47) [6]. A PFS or OS win here would be regulatorily meaningful, particularly for approval in the HER2-expressing subset, but the commercial narrative shifts from best-in-class first-line to a niche alternative for HER2-positive patients who progress on or cannot tolerate EV plus pembro. Otherwise the trial is standard: randomized, blinded central review, well-powered for PFS, run by a sponsor with global oncology infrastructure.

Our model estimates a 33% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual, its light or open-label blinding, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk. The comparator arm is no longer standard of care in most Western markets. A statistical win over platinum chemo does not answer the clinically important question of whether disitamab vedotin plus pembro is better, worse, or comparable to EV plus pembro, and the trial was not designed to answer that [6]. Biomarker risk. HER2 IHC 1+/2+/3+ captures a heterogeneous population, and the correlation between HER2 IHC level and ADC response in bladder cancer is not as clean as it is in breast cancer. If activity concentrates only in IHC 3+, the addressable market shrinks. Addressable market context. US metastatic urothelial cancer incidence sits at roughly 15,000 to 20,000 patients per year. At the trial's IHC 1+ eligibility (roughly 40 to 60% of mUC), the maximum US label population is on the order of 6,000 to 12,000 patients per year. If real-world use collapses to IHC 3+ only, that shrinks to roughly 2,000 to 4,000 patients per year. In either case, this is a niche population inside a market already occupied by EV plus pembro, and revenue potential is bounded accordingly. Safety risk. MMAE-based ADCs carry peripheral neuropathy and ocular toxicity as class effects. Enfortumab vedotin (also MMAE) has boxed warnings for skin reactions and hyperglycemia. Combining an MMAE ADC with pembrolizumab may compound immune-mediated adverse events in the real world even if the pivotal trial tolerability reads as manageable. Commercial risk. Pfizer already owns EV plus pembro through the Seagen acquisition, so positioning disitamab vedotin against its own franchise is awkward [5]. The most defensible position is second-line after EV plus pembro in HER2-expressing patients, but the current Phase 3 does not test that setting. Value share risk. RemeGen retains ex-China milestones and tiered royalties on ex-China sales under the 2021 license [7], so a portion of Western economics flows out of Pfizer. Execution risk. Enrollment has closed, so remaining execution risk is data maturity and readout timing rather than accrual. Regulatory risk is moderate: FDA may push for context against current standard of care, not just against platinum chemo.

Worth watching with disciplined expectations. The signal to look for is the magnitude and durability of PFS benefit in the HER2 IHC 2+/3+ subgroup, not just the intent-to-treat population. Prior-phase data already sets a benchmark: RC48G001 Phase 2 reported ORR near 55% in both HER2-positive and HER2-low urothelial cancer as a single agent [8], so the Phase 3 combination with pembrolizumab needs to clearly exceed that to justify the combination approach. If disitamab vedotin plus pembro roughly matches EV plus pembro PFS numbers (median around 12 months) in a HER2-selected subset with a differentiated tolerability profile or a real efficacy edge in HER2-high patients, there is a defensible second-line or biomarker-defined first-line story. If the PFS benefit in HER2-high patients is not clearly better than what EV plus pembro already delivers unselected, the asset is boxed in commercially. The closer catalyst is the ongoing Phase 2 NCT04879329, which will read out cohort-level ORR and duration of response data useful for calibrating expectations before the Phase 3 [4]. On the money side: Padcev generated $6.4B in 2024 revenue in Pfizer's oncology reporting [5], so Pfizer is already deeply committed to EV plus pembro as the first-line franchise. The same company holding two competing bladder-cancer ADCs creates a positioning question that management will eventually have to answer on an earnings call, and RemeGen's royalty stake on ex-China sales means Pfizer does not fully own the disitamab vedotin economics even if the trial wins. That is the moment to check back.